Title Category Credit Event datesort ascending Cost
Optimizing Outcomes in Iron Deficiency Anemia: Adaptive Approaches for the OB/GYN
  • AMA PRA Category 1 Credit™
  • Participation
10/17/2020 $0.00 Iron deficiency anemia is a far-reaching condition of immense clinical impact in women’s health, with implications ranging from the global, epidemiological scale, to individual OB/GYN practices, and most importantly, to individual patients. As such, this educational initiative is designed to address the myriad challenges of iron deficiency anemia (IDA) in women’s health using a dynamic, multifaceted approach targeted to OB/GYNs.
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
09/29/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Neurology Residents Scholar Program
  • Neurology
09/24/2020 $0.00 The NRSP is an epilepsy-focused educational opportunity for second- and third-year neurology residents. NRSP is an intensive multi-day course that addresses all clinical aspects of epilepsy, including the latest developments in diagnosis and treatment. Founded by the late Dr. John Gates of the Minnesota Epilepsy Group, PA, this is the NRSP’s eighteenth year educating residents about epilepsy to improve patient care.
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
09/22/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Adaptive Protocols and Practical Strategies for the Use of Novel Anticoagulation Reversal Agents
  • Cardiology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
09/19/2020 $0.00 This interprofessional, community Grand Rounds initiative is targeted to addressing the professional practice of physicians, pharmacists, nurse practitioners, physician assistants, nurses, and other healthcare professionals, who manage patients who are taking anticoagulation therapy, and who may require reversal agents for direct oral anticoagulants to address acute bleeding complications.
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
09/17/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
ONS Bridge — Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
09/17/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine
  • Oncology
  • ANCC
  • Participation
09/15/2020 $0.00 Attendees will gain an appreciation of the latest advances in non-small cell lung cancer (NSCLC), including the nurse’s role in comprehensive biomarker testing strategies and biomarker-driven treatment approaches. Expert faculty will reflect on the lung cancer tumor board, with emphasis on the appropriate selection of targeted therapy based on patient- and biomarker-specific factors in oncogenic driver mutations.
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
09/12/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Immune-Related Adverse Events with Cancer Immunotherapy: Case-Based Challenges for the Oncology Nurse
  • Oncology
  • ANCC
  • Participation
09/12/2020 $0.00 Early identification of irAEs and initiation of systemic immunosuppression can improve outcomes without compromising the efficacy of immune checkpoint inhibition. As front-line caregivers, oncology nurses are optimally positioned to quickly identify such adverse events and employ appropropriate management strategies.

Pages